Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-04
2005-01-04
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C540S496000, C540S497000, C540S498000, C540S499000, C540S504000, C540S517000, C540S518000
Reexamination Certificate
active
06838455
ABSTRACT:
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
REFERENCES:
patent: 3598859 (1971-08-01), Yates et al.
patent: 3657341 (1972-04-01), Thorne
patent: 4080449 (1978-03-01), Croisier et al.
patent: 4410520 (1983-10-01), Watthey
patent: 4473575 (1984-09-01), Watthey
patent: 4477464 (1984-10-01), Slade et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4977168 (1990-12-01), Bernat et al.
patent: 5015639 (1991-05-01), Berger et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5238932 (1993-08-01), Flynn et al.
patent: 5247080 (1993-09-01), Berger et al.
patent: 5283241 (1994-02-01), Bochis et al.
patent: 5284841 (1994-02-01), Chu et al.
patent: 5324726 (1994-06-01), Bock et al.
patent: 5360802 (1994-11-01), Chambers et al.
patent: 5420271 (1995-05-01), Warshawsky et al.
patent: 5478857 (1995-12-01), Clemens et al.
patent: 5486541 (1996-01-01), Sterling et al.
patent: 5502048 (1996-03-01), Chapdelaine et al.
patent: 5519061 (1996-05-01), Youdim et al.
patent: 5532415 (1996-07-01), Youdim et al.
patent: 5556969 (1996-09-01), Chambers et al.
patent: 5633251 (1997-05-01), Claremon et al.
patent: 5656626 (1997-08-01), Chapdelaine et al.
patent: 5658901 (1997-08-01), Claremon et al.
patent: 5672598 (1997-09-01), De et al.
patent: 5712397 (1998-01-01), Esser et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 0061187 (1982-09-01), None
patent: 0167919 (1986-01-01), None
patent: 0284256 (1988-09-01), None
patent: 0349949 (1990-01-01), None
patent: 0376849 (1990-07-01), None
patent: 0434360 (1991-06-01), None
patent: 0434364 (1991-06-01), None
patent: 0434369 (1991-06-01), None
patent: 0490590 (1992-06-01), None
patent: 0514133 (1992-11-01), None
patent: 0523845 (1993-01-01), None
patent: 0549039 (1993-06-01), None
patent: 0647632 (1995-04-01), None
patent: 0652009 (1995-06-01), None
patent: 0667344 (1995-08-01), None
patent: 0677517 (1995-10-01), None
patent: 0732399 (1996-09-01), None
patent: 0778266 (1997-11-01), None
patent: 1519495 (1978-07-01), None
patent: 1573931 (1980-08-01), None
patent: 2272439 (1994-05-01), None
patent: 2290788 (1996-01-01), None
patent: 06145148 (1994-05-01), None
patent: 04210967 (1994-08-01), None
patent: 07304770 (1995-11-01), None
patent: 10072444 (1998-03-01), None
patent: 9201683 (1992-02-01), None
patent: 9216524 (1992-10-01), None
patent: 9319052 (1993-09-01), None
patent: 9319063 (1993-09-01), None
patent: 9404531 (1994-03-01), None
patent: 9405693 (1994-03-01), None
patent: 9407486 (1994-04-01), None
patent: 9410569 (1994-05-01), None
patent: 9503289 (1995-02-01), None
patent: 9503290 (1995-02-01), None
patent: 9509838 (1995-04-01), None
patent: 9514671 (1995-06-01), None
patent: 9521840 (1995-08-01), None
patent: 9523810 (1995-09-01), None
patent: 9525118 (1995-09-01), None
patent: 9532191 (1995-11-01), None
patent: 9605839 (1996-02-01), None
patent: 9616981 (1996-06-01), None
patent: 9620725 (1996-07-01), None
patent: 9622966 (1996-08-01), None
patent: 9640146 (1996-12-01), None
patent: 9640653 (1996-12-01), None
patent: 9640654 (1996-12-01), None
patent: 9640655 (1996-12-01), None
patent: 9640656 (1996-12-01), None
patent: 9730072 (1997-08-01), None
patent: 9738705 (1997-10-01), None
patent: 9800405 (1998-01-01), None
patent: 9825930 (1998-06-01), None
patent: 9828268 (1998-07-01), None
patent: 9838177 (1998-09-01), None
Aquino, et al. Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger.”J. Med. Chem.39: 562-569 (1996).
Blade-Font. “Facile Synthesis of γ-,δ-, and ε-lactams by Cyclodehydration of ω-amino Acids on Alumina or Silica Gel.”Tetrahedron Letters21: 2443-2446 (1980).
Bock, et al. “Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones.”J. Org. Chem.52: 3232-3239 (1987).
Bock, et al. “An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one.”Tet. Lets.28(9): 939-942 (1987).
Bock, et al. “Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists.”Bioorg. and Med. Chem. Lets.2(9):987-998 (1994).
Chambers, et al. “L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor.”Bioorg. and Med. Chem. Letts.3(10):1919-1924 (1993).
Chartier-Harlin, et al. “Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-Amyloid precursor protein gene.”Nature.353(31): 844-846 (1991).
Citron, et al. “Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-amyloid protein production.”Nature360:672-674 (1992).
Cordell. “B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease.”Ann. Rev. Pharmacol. Toxicol.34:69-89 (1994).
Evans, et al. “Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists.”J. Med. Chem.31:2235-2246 (1988).
Evans, et al. “Molecular Mimicry and the Design of Peptidomimetrics.”Molecular Mimicry in Health and Disease.(A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-34.
Finizia, et al. “Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups.”Bioorg.&Medicinal Chemistry Letters.6(24):2957-2962 (1996).
Glenner, et al. “Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein.”Biochem. Biophys. Res. Commun.120(3): 885-890 (1984).
Goate, et al. “Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.” Letters toNature.349: 704-706 (1991).
Hirst, et al. “Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent.”J. Med. Chem.39: 5236-5245 (1996).
Hofmann, et al. “Interactions of Benzodiazepine Derivatives with Annexins.”J. Biol. Chem.273(5):2885-2894 (1998).
Johnson-Wood, et al. “Amyloid precursor protein processing and Aβ42deposition in a transgenic mouse model of Alzheimer's disease.”PNAS USA.94: 1550-1555 (1997).
Ksander, G.M., et al. “Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors.”J. Med. Chem.37: 1823-1832 (1994).
Lowe, et al. “A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist.”Bioorg. and Med. Chem. Lets.5(17): 1933-1936 (1995).
Lowe, et al. “5-Phenyl-3-ureidobenzzazepin-2-ones as Cholecystokinin-B Receptor Antagonists.”J. Med. Chem.37: 3789-3811 (1994).
Mullan, et al. “A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of β-Amyloid.”Nature Geneticsm1: 345-347 (1992).
Murrell, et al. “A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease.”Reports.97-99 (1991).
Papadopoulos, et al. “Anodic Oxidation of N-Acyl and N-Alkoxylcarbonyl Dipeptide Esters as a Key Steop for the Formation of Chiral Heterocyclic Synthetic Building Blocks.”Tetrahedron47(4/5):563-572 (1991).
Patel, et al. “Biological Preperties of the Benzodiazepine Amidine Derivative L-740,093, a Choleycystokinin-B/Gastrin Receptor Antagonist with High Affinity in vitro and High Potency in vivo.”Molecular Pharmacology.46:943-948 (1994).
Rittle, et al. &#x
Audia James E.
Porter Warren J.
Shi Qing
Stack Douglas R.
Thompson Richard C.
Athena Neurosciences, Inc.
Burns Doane , Swecker, Mathis LLP
Eli Lilly & Company
Kifle Bruck
LandOfFree
Deoxyamino acid compounds, pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Deoxyamino acid compounds, pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deoxyamino acid compounds, pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382169